FMC beats on Q2 adjusted EBITDA but slashes full-year outlook; licensing deal offers temporary cash relief

What happened

FMC Corporation reported Q2 2026 revenue down 17% year-over-year to $867 million and a GAAP net loss of $187 million, though adjusted EBITDA of $153 million exceeded the high end of guidance. Management lowered full-year 2026 guidance, citing a more challenging macro environment, with adjusted EBITDA now seen at $620–$680 million, a 23% decline at the midpoint. The company announced a $200 million upfront licensing payment for rimisoxafen, which lifted free cash flow guidance to $75–$225 million, providing a one-time liquidity boost. Underlying operational trends remain weak: organic revenue fell 22%, and the GAAP loss widened significantly, underscoring persistent pricing and volume pressures. The licensing cash buys time but does not alter the need for a sustainable improvement in operating cash flow and debt reduction, as highlighted in the DeepValue master report.

Implication

The Q2 adjusted EBITDA beat is a minor positive, but the full-year outlook cut reflects a tough ag cycle and competitive pricing that continue to erode profitability. The $200 million licensing payment temporarily bolsters liquidity, yet it is non-recurring, and free cash flow without it remains anemic. The master report’s call to wait for evidence of normalized collections and sustainable operating cash flow remains valid; until FMC demonstrates consistent cash generation without factoring, the risk of covenant pressure and further impairments persists. Investors should focus on Q3 trends and any signs of working-capital stabilization. The stock remains a leveraged bet on a cash recovery that is yet to materialize.

Thesis delta

The $200 million licensing inflow reduces immediate liquidity risk but underscores the company’s dependency on non-operating cash sources. The core thesis—that sustainable value requires an inflection in collections and operating cash flow—remains unchanged. The cash buys time, but the fundamental path to recovery is still unpaved.